Tranzactioneaza Adaptimmune Therapeutics Plc Adr (US.ADAP) - 0.7716 USD (%) Tranzactioneaza

1D
1W
1M
3M
6M
1Y
5Y
Max

Indici

Bid 0.7712 USD
Ask 0.7790 USD
Minim 0.7879 USD
Maxim 0.8304 USD
Pret referinta 0.8295
Volum -
Volum ultima zi 1
Max 52 sapt 2.0500 USD
Min 52 sapt 0.4330 USD

Descriere companie

Adaptimmune Therapeutics plc (https://www.adaptimmune.com/) is a clinical-stage biopharmaceutical company that focuses on the development of novel cancer immunotherapy products for people with cancer. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with ADP-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.

Informatii companie

Nume

Adaptimmune Therapeutics PLC ADR